hair loss; fatigue/unusual tiredness; fever; heavy periods; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority. regulatory number: gb-mhra-webcovid-202202212348331540-ggk0w (agency). other case identifier(s): gb-mhra-adr 26633923 (agency). a female patient received bnt162b2 (comirnaty), administration date 15dec2021 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "suspected covid-19" (ongoing), notes: unsure when symptoms started. the patient's concomitant medications were not reported. vaccination history included: bnt162b2 (dose 2, single; lot number: unknown), for covid-19 immunisation, reaction(s): "suspected covid-19", "suspected covid-19"; bnt162b2 (dose 1, single; lot number: unknown), for covid-19 immunisation, reaction(s): "suspected covid-19", "suspected covid-19". the following information was reported: alopecia (disability, medically significant), outcome "not recovered", described as "hair loss"; heavy menstrual bleeding (disability, medically significant) with onset 06jan2022, outcome "not recovered", described as "heavy periods"; fatigue (disability, medically significant), outcome "unknown", described as "fatigue/unusual tiredness"; pyrexia (disability, medically significant), outcome "unknown", described as "fever". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. the report of the patient was related to possible inflammation of the heart (myocarditis or pericarditis) however, the symptoms did not lead to a hospital stay and diagnosis was not made by a medical professional. no blood tests, such as for certain proteins (called troponin) that signal heart muscle damage were taken. the patient was not enrolled in clinical trial. the patient had not been tested positive for covid-19 since having the vaccine. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected